TY - JOUR T1 - Immunosuppression for interstitial lung disease in systemic sclerosis JF - European Respiratory Review JO - EUROPEAN RESPIRATORY REVIEW SP - 236 LP - 243 DO - 10.1183/09059180.00001813 VL - 22 IS - 129 AU - Susanna Cappelli AU - Serena Guiducci AU - Silvia Bellando Randone AU - Marco Matucci Cerinic Y1 - 2013/09/01 UR - http://err.ersjournals.com/content/22/129/236.abstract N2 - The efficacy of immunosuppressors in the treatment of systemic sclerosis-interstitial lung disease is still matter of controversy. In this review we will analyse the evidence that immunosuppressors, despite not being able to reverse fibrotic changes, may help in slowing disease progression. Induction treatment with cyclophosphamide should be started as soon as possible in patients at risk for progression. Mycophenolate mofetil and rituximab have to be considered in patients who are unable to tolerate cyclophosphamide. After remission, maintenance treatment with mycophenolate mofetil or azathioprine should be started in order to preserve the benefits achieved during the induction treatment. ER -